Scarica l'app Stockscreener
0.79
0.01%
0.000100
Precedente Chiudi:
$0.7899
Aprire:
$0.754799
Volume 24 ore:
40,532
Relative Volume:
0.11
Capitalizzazione di mercato:
$9.78M
Reddito:
$123.30K
Utile/perdita netta:
$-11.95M
Rapporto P/E:
-0.5123
EPS:
-1.5421
Flusso di cassa netto:
$-12.57M
1 W Prestazione:
+10.49%
1M Prestazione:
-13.19%
6M Prestazione:
-19.40%
1 anno Prestazione:
-54.92%
Intervallo 1D:
$0.7218
$0.79
Intervallo di 1 settimana:
$0.72
$0.85
Portata 52W:
$0.548
$2.11
Aprea Therapeutics Inc Stock (APRE) Company Profile
Nome
Aprea Therapeutics Inc
Settore
Industria
Telefono
215-948-4119
Indirizzo
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
0.79 | 9.78M | 123.30K | -11.95M | -12.57M | -1.5421 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2020-12-28 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-12-16 | Iniziato | Berenberg | Buy |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-06-22 | Iniziato | H.C. Wainwright | Neutral |
| 2020-04-21 | Iniziato | Robert W. Baird | Outperform |
| 2019-10-28 | Iniziato | JP Morgan | Neutral |
| 2019-10-28 | Iniziato | Morgan Stanley | Equal-Weight |
| 2019-10-28 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Aprea Therapeutics Inc Borsa (APRE) Ultime notizie
APRE Forecast — Price Target — Prediction for 2027 - TradingView
Aprea Therapeutics, Inc. Actuals & Estimates (NASDAQ:APRE) - TradingView
Aprea Therapeutics Inc (APRE) Institutional Confidence - TradingKey
Aprea Therapeutics Inc (APRE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Precision Medicine Strategies Expand Opportunities for Targeted Cancer Treatment, Says Dr Oren Gilad, Aprea Therapeutics - BioPharm International
Aprea Therapeutics Inc (APRE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aprea Shareholders Approve Directors, Reverse Split Flexibility - The Globe and Mail
Aprea Therapeutics Inc (APRE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aprea Therapeutics Inc (APRE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aprea Therapeutics Shareholders Approve Reverse Stock Split and Key Proposals at 2026 Annual Meeting - Minichart
Aprea Therapeutics Inc (APRE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aprea Therapeutics shareholders approve director elections and reverse stock split - Investing.com Nigeria
Aprea Therapeutics shareholders approve director elections and reverse stock split By Investing.com - Investing.com South Africa
Aprea Therapeutics Inc (APRE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Aprea Therapeutics Inc (APRE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aprea Therapeutics Inc (APRE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Aprea Therapeutics Stock Rises After Company Reports Second Unconfirmed Case Of Tumor Reduction In Trial - Stocktwits
[Form 4] Aprea Therapeutics, Inc. Insider Trading Activity - Stock Titan
APRE: All agenda items, including director elections and reverse stock split, were approved - TradingView
Oppenheimer Initiates Aprea Therapeutics(APRE.US) With Buy Rating, Announces Target Price $5 - Moomoo
This Aprea Therapeutics analyst begins coverage on a bullish note; here are top 3 initiations for Thursday - MSN
Aprea Reports Early Tumor Responses in Phase 1 APR-1051 Study - MyChesCo
APRE Q1 2026 Earnings: Narrower Loss Surpasses Expectations Amid Ongoing Clinical DevelopmentManagement Guidance Update - newsline.com
APRE Q1 2026 Earnings: Narrower-than-Expected Loss as Clinical Pipeline AdvancesSpecial Dividend Alert - newsline.com
APRE Q1 2026 Earnings: EPS Surpasses Estimates Amid Pre-Revenue StageEarnings Surprise Score - newsline.com
Aprea Expands Cancer Trial After Early Tumor Responses - MyChesCo
Aprea's WEE1 Drug Shows Early Promise in Hard-to-Treat Cancers - BriefGlance
H.C. Wainwright Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $1.2 - Moomoo
Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors - The Manila Times
Cancer trial drug APR-1051 posts partial responses at ASCO 2026 - Stock Titan
Aprea Therapeutics (APRE) Edges Higher Amid Light Trading; Key Resistance at $0.99 in FocusOBV Divergence - The Legal Advocate
Aprea Therapeutics (APRE) Edges Higher Amid Low Volume TradingATR Stop - The Legal Advocate
Aprea Therapeutics Inc. (APRE) Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline Amid Clinical ProgressAnalyst Drop Coverage - newsline.com
Aprea Therapeutics (APRE) upgraded to buy: Here's what you should know - MSN
Aprea Expands Cancer Trial After $30 Million Financing - MyChesCo
Aprea Therapeutics (APRE) Upgraded to Buy: Here's What You Should Know - sharewise.com
Vestal Point reports 9.9% stake in Aprea Therapeutics (NASDAQ: APRE) - Stock Titan
Aprea Therapeuticsfiles for resale of up to 5.5 million shares by selling stockholdersSEC filing - marketscreener.com
[424B7] Aprea Therapeutics, Inc. Prospectus Filed Pursuant to Rule 424(b)(7) - Stock Titan
Aprea Therapeutics 1Q Research and Development Expenses $1.6M >APRE - Moomoo
Wedbush Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Cuts Target Price to $6 - Moomoo
Maxim Group Maintains Aprea Therapeutics(APRE.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Analyst Reiterates Buy on Aprea as APR-1051 Data and Cash Runway Support Unchanged $5 Price Target - TipRanks
Press Release: Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - Moomoo
Wedbush Adjusts Price Target on Aprea Therapeutics to $6 From $7, Maintains Outperform Rating - Moomoo
Aprea Therapeutics, Inc. Q1 2026 10-Q Report – Financials, Risk Factors, and Forward-Looking Statements - Minichart
Aprea Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Aprea Therapeutics Inc Azioni (APRE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):